Life sciences company Sanford Biosciences, formerly Sanford Applied Biosciences, researches and develops animal platform technology to produce fully human antibodies.
QurAlis Corporation secures an $88 million Series B funding round led by EQT Life Sciences, raising total capital to $143.5 million. The clinical-stage biotech firm focuses on precision medicines targeting ALS and other neurodegenerative diseases with genetically validated pathways. The oversubscribed round highlights strong investor interest in its pipeline of potential treatments.
QurAlis Corporation secures an oversubscribed $88 million Series B funding round. The biotechnology company, currently in clinical stages, attracts investment led by EQT Life Sciences. This capital infusion supports further development of its pipeline in advanced therapeutics.
QurAlis Corporation secures an oversubscribed $88 million Series B round to advance precision medicines for ALS and other neurodegenerative diseases. The company targets genetically validated disease mechanisms, expanding its total funding to $143.5 million. This financing supports its clinical-stage pipeline of potential treatments for unmet medical needs.
EnBiotix secures $11 million in pre-merger financing from Vectura Group plc, the Cystic Fibrosis Foundation, and Sanford Biosciences LLC. The company specializes in rare disease treatments, with a current focus on chronic respiratory disorders. This funding round supports its development pipeline ahead of a potential merger.
QurAlis Corporation secures **$42 million in Series A funding** to advance precision therapeutics for **amyotrophic lateral sclerosis (ALS)** and other neurological diseases. The financing brings total raised capital to **$50.5 million**, supporting research and development of novel treatment approaches. The company focuses on targeted therapies to address unmet medical needs in neurodegenerative conditions.